Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials

Inclusion and exclusion criteria for this systematic review and IPD meta-analysis

Trials were eligible for inclusion if they were individual or cluster RCTs with either longitudinal follow-up or repeated cross-sectional data collection, were conducted in low- or middle-income countries (24), provided SQ-LNS (< ∼125 kcal/d) to study participants for at least three months during any part of the age range between 6-24 months of age, and reported at least one outcome of interest.

We excluded trials in which SQ-LNS was used for the treatment, not prevention, of malnutrition (i.e., only children with moderate to severe malnutrition were eligible to participate), as well as studies specifically conducted in hospitalized populations or among children with a pre-existing disease. Trials were excluded if the only available comparison group received other types of non-LNS child supplementation (e.g., multiple micronutrient powder, fortified blended food) or if SQ-LNS provision was combined with an additional supplemental food or nutrients within a single arm (e.g., SQ-LNS + food rations vs. control), and there was no appropriate comparison group that would allow isolation of the SQ-LNS effect (e.g., food rations alone).

Trials in which there were multiple relevant SQ-LNS interventions (e.g., varying dosages or formulations of SQ-LNS in different arms), or that combined provision of SQ-LNS with other non-nutritional interventions (e.g., water, sanitation and hygiene (WASH)), were eligible fo inclusion. In such trials, all arms that provided SQ-LNS were combined into one group, and all non-LNS arms were combined into a single comparison group for each trial (herein labeled “Control”), excluding intervention arms that received non-LNS child supplementation (e.g., multiple micronutrient powder, fortified-blended food). We also conducted a sensitivity analysis restricting the comparison to specified contrasts of intervention arms within multiple intervention trials (see below).

Individual children were included in the analyses if their age at baseline allowed them to receive at least three months of intervention (supplementation or control group components) between 6 and 24 months of age, and if biochemical outcome assessment occurred within 3 months of the intended, trial-defined end of supplementation.

Search methods and identification of studies

We identified potential studies for inclusion in the IPD analysis from a recent systematic review and meta-analysis of LNS (7). We then repeated the database search strategy employed by Das et al.(7), using the same keyword and controlled vocabulary search terms, to capture additional studies (both completed and on-going) indexed in one of 23 international or regional electronic databases and 2 trial registers between July 1, 2018 and May 1, 2019 (see Supplemental Methods). One of the authors (KRW) reviewed the titles and abstracts of all studies included in the 2019 Cochrane review, as well as the additional studies identified by the repeated search strategy, to select all potentially relevant studies for full text review. The full-text reports of all potentially relevant records were reviewed. Trials were assessed against the inclusion and exclusion criteria detailed above. In September 2019, the same author reviewed the previously identified on-going studies that met inclusion and exclusion criteria to determine if results for outcomes of interest had been subsequently published.

Data collection and harmonization

We invited all principal investigators of eligible studies to participate in this IPD meta-analysis. Individual investigators were asked to provide de-identified individual participant data (primary data) for pre-specified variables (defined above and detailed in a data dictionary provided to investigators). The IPD analyst (CDA) collected and managed the individual participant data, and communicated with investigators to request any missing variables or other information.

IPD integrity

We conducted a complete-case, intention to treat analysis (25). We checked data for completeness by crosschecking sample sizes with study protocols and publications. We also crosschecked the data provided against reported values for each trial to ensure consistency. Variables were assessed for outliers and low frequency categories. Relevant model assumptions were assessed (e.g. Shapiro-Wilk normality testing and Breusch-Pagan heteroscedasticity testing) and outcome variables were appropriately transformed before subsequent analyses, as necessary.

Assessment of risk of bias in each study and quality of evidence across studies

Two independent reviewers (KRW and CDA) assessed risk of bias using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (26). We assessed each trial against the following criteria: random sequence generation and allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. Reviewers also assessed the quality of evidence for each primary and secondary outcome across all trials based on the five GRADE criteria: risk of bias, inconsistency of effect, imprecision, indirectness and publication bias (27). Any discrepancies were resolved by discussion or consultation with the core working group, as needed.

Specification of outcomes and effect measures

We specified outcomes a priori in the statistical analysis plan (22). Outcomes of interest are listed in Box 1. For the estimation of the main effects, we pre-specified hemoglobin concentration, anemia, moderate-to-severe anemia, and biomarkers of iron status as primary outcomes in the statistical analysis plan, and present results for all outcomes. Hemoglobin concentrations were adjusted for altitude, as necessary (28). Ferritin, sTfR, ZPP, zinc, retinol and RBP concentrations were adjusted for inflammation (i.e., C-reactive protein (CRP) and/or α-1-acid glycoprotein (AGP) concentrations, as available), using a regression correction approach adapted from the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project and described in detail elsewhere (29); results are presented for inflammation-adjusted concentrations.

The principal measure of effect for normally distributed continuous outcomes was the mean difference (MD) between the intervention and comparison groups at endline, defined as the principal post-intervention time point as reported by each longitudinal trial or at an age closest to the end of the supplementation period for cross-sectional samples. For natural log transformed outcomes, the principal measure of effect was the ratio of geometric means (GMR) between the two groups at endline. For binary outcomes, the principal measure of effect was the prevalence ratio (PR; relative difference in proportions between groups) at endline. We also estimated prevalence differences (PD; in absolute percentage points) but considered them as secondary assessments of binary outcomes because such estimates are less consistent than prevalence ratios (26).

The treatment comparison of interest was child SQ-LNS vs. control. In the intervention groups, child SQ-LNS may have been provided along with other nutrition-sensitive co-interventions (e.g., WASH or child morbidity monitoring and treatment). The control groups consisted of passive or active comparison arms which provided no intervention or an intervention without any type of LNS or other child supplement (e.g., WASH). Several trials (or arms within trials) have delivered SQ-LNS to children whose mothers received maternal SQ-LNS during pregnancy and postpartum. We had originally planned to include trial arms that provided both maternal and child SQ-LNS in a sensitivity analysis only (i.e., the all-trials analysis), as maternal supplementation may have an additive effect on child outcomes when SQ-LNS is provided to both mothers and to their children. However, to maximize study inclusion and participant sample size, we decided post-hoc that if the main effects did not differ between the child-LNS-only analysis and the all-trials analysis (including maternal plus child LNS arms) by more than 20% for mean differences or by more than 0.05 for ratios of geometric means or prevalence ratios, the results of the all-trials analyses would be presented as the principal findings. Two additional sensitivity analyses were also conducted, as described below.

Synthesis methods and exploration of variation in effects

We separately investigated: 1) full sample main effects of the intervention, 2) effect modification by study-level characteristics, and 3) effect modification by individual-level characteristics. For all three sets of analyses, we used a two-stage approach, which is preferred when the analysis includes cluster-randomized trials (30). In the first stage, we generated intervention effect estimates within each individual study. For longitudinal studies, we controlled for baseline status of the outcome variable, if available, to gain efficiency. For cluster-randomized trials, we used robust standard errors with randomization clusters as the independent unit (31). In the second stage, we pooled the first stage estimates using inverse-variance weighted fixed effects. We also conducted sensitivity analyses in which we pooled estimates using inverse-variance weighted random effects (32). Pooled estimates were only generated if three or more study or sub-study SQ-LNS vs. control comparisons were available for inclusion in the pooled estimate (e.g., 3 or more comparisons were represented within a study-level effect modification category).

• 1) Full sample main effects of the intervention: We first estimated the intervention effect for each study. We then pooled the first stage estimates to generate a pooled point estimate, 95% confidence interval, and corresponding p-value.

• 2) Effect modification by study level characteristics: We identified potential study-level effect modifiers prior to receipt of data, and categorized individual studies based on the distribution of effect modifier values across all studies (Box 2). We used random effects meta-regression to test the association between each effect modifier and the intervention. In the first stage of analysis, we estimated the parameter corresponding to the intervention effect as described above. In the second stage, we used a bivariate random effects meta-regression to test the association between the study-specific intervention effect and study level characteristics.

• 3) Effect modification by individual level characteristics: We identified potential individual-level characteristics based on a comprehensive review of effect modifiers considered by individual trials (either listed a priori in statistical analysis plans or as published) or selected based on biological plausibility (Box 2). We estimated the parameter corresponding to the interaction term of the effect modifier and the intervention for each study (31), as follows. For categorical effect modifiers, we first recoded them to create binary variables if needed, and then determined the interaction between the intervention and the binary effect modifier. We transformed continuous effect modifiers into binary variables by modeling the relationship within each study using splines and then pooling the first stage estimates to generate a pooled, fitted line. We defined programmatically useful dichotomous cutoffs based on the pooled fitted spline results and relevant context. We then generated pooled intervention effect estimates within each category to determine how the intervention effect in one subgroup differed from the intervention effect in the specified reference subgroup.

In all analyses, heterogeneity was assessed using I² and Tau² statistics, within strata when relevant (33). We used a p-value of < 0.05 for main effects and a p-diff or p-for-interaction < 0.10 for effect modification by study-level or individual-level characteristics, respectively. Because biochemical outcomes are inter-related and the effect modification analyses are inherently exploratory, we did not adjust for multiple hypothesis testing (34).

To aid in interpretation of individual-level effect modification, we evaluated the results for binary outcomes to identify what we will call the “cutoff effect”. The distribution of the continuous outcome relative to the cutoff for the corresponding binary outcome (e.g., distribution of hemoglobin around the 110 g/L anemia cutoff) in the 2 effect modifier subgroups can influence the prevalence ratio and prevalence difference. When the mean in each of the 2 subgroups falls in a different location relative to the cutoff, the proportion of children close to the cutoff may be different between subgroups. This can lead to a greater reduction in the adverse binary outcome within one subgroup than within the other even if the shift in the mean value due to SQ-LNS is the same in both subgroups. To examine this, we simulated what would happen if we shifted the distribution of the non-reference effect modification subgroup to align with the reference subgroup (see Box 2), while maintaining the observed intervention effect mean difference in the continuous outcome within each subgroup. Based on ad-hoc, pragmatic criteria, if the p-for-interaction shifted from < 0.1 to > 0.2, we concluded that the cutoff effect explained the apparent effect modification; if it shifted from < 0.1 to > 0.1 but < 0.2, we concluded that the cutoff effect partially contributed to the apparent effect modification.

Additional sensitivity analyses

For the child SQ-LNS only and all-trials analyses, we combined all non-LNS arms into a ‘Control’ group for that trial. However, substantial variations in trial design (e.g., integration of SQ-LNS supplementation with WASH interventions or enhanced morbidity monitoring and treatment, use of passive vs. active control arms) might influence the effect size of the estimates. Therefore, we conducted sensitivity analyses based on child-LNS only analyses in which we (1) separated the comparisons within trials that contained multi-component arms, thus restricting the comparisons to pairs of arms with the same non-nutrition components (e.g. SQ-LNS+WASH vs. WASH and SQ-LNS vs. control) or (2) excluded passive control arms, i.e., restricting the comparison to SQ-LNS vs. active control arms (Supplemental Table 1). These analyses are considered exploratory.

Literature search and trial characteristics

We identified 15 trials that met our inclusion criteria for the child SQ-LNS only and/or all-trials analyses, 13 of which (35–48) provided individual participant biochemical data and are included in this analysis (9-13, 15-17, 39, 46-48) (Figure 1). In one study biochemical data were not collected (49), and investigators for one trial were unable to participate (14). An overview of each trial included in the analysis is provided in Table 1; additional details are provided in Supplemental Table 1. One trial was designed a priori to present results separately for HIV exposed and HIV un-exposed children (47, 48); therefore we considered it herein as two comparisons in all analyses and presentation of results. The PROMIS trials in Burkina Faso and Mali each included a longitudinal cohort and repeated cross-sectional surveys (at baseline and endline); however biochemical samples were collected only in the cross-sectional surveys (39, 46).

• Download figure
• Open in new tab

Figure 1:

Study flow diagram

The 13 trials in these analyses were conducted in 9 countries in Sub-Saharan Africa and South Asia, and included a total of 15,946 infants and young children with biochemical data. Eleven trials began child supplementation with SQ-LNS at 6 months of age; for the remaining two trials, SQ-LNS supplementation began when infants were 9 months of age in one (38), and between 6-11 months of age in the other (43). Supplementation occurred for 6 to 18 months in duration, depending on the trial. Four trials included intervention arms that also provided SQ-LNS to mothers during pregnancy and the first 6 months postpartum (36, 41, 43, 44). The majority of trials provided a peanut- and milk-based SQ-LNS providing approximately 120 kcal/d and 1 RDA of most micronutrients (Supplemental Table 2). However, the iron dose per day varied among trials. Four trials provided 9 mg/d iron (36, 37, 40, 42), 8 trials provided 6 mg/d iron (38, 39, 41, 43–48), and one trial provided 3.3 – 9 mg/d iron depending on study arm and child age (35).

Categorizations and descriptive information for potential study- and individual-level effect modifiers, by trial, are presented in Supplemental Tables 3 - 4, respectively. Characteristics ranged widely across trials. Based on data from national surveys, the prevalence of anemia among children 6-59 months ranged from 36% to 88%, and the prevalence of malaria (presumed and confirmed cases) ranged from < 1% to 59% (50). Based on data from individual trials, the study-level prevalence of elevated CRP ranged from 11% to 34% and the prevalence of elevated AGP ranged from 29% to 68%.

All trials measured hemoglobin concentration (n = 15,398), and 11 reported at least one biomarker of iron status (n = 1,542 – 3,078) (Supplemental Table 1, Supplemental Table 5). Fewer studies assessed zinc (3 studies; n = 1,133) or vitamin A (9 studies; n = 1,236 – 2,314) status. Assessments of hepcidin, folate and vitamin B12 concentrations were planned in 3-4 studies each, but data were not yet available from a sufficient number of trials to be included in the present analysis. Median biomarker concentrations and prevalence of dichotomous study outcomes among control groups by trial are presented in Table 1 (anemia and iron deficiency) and Supplemental Table 6 (all outcomes). In control groups at endline, the prevalence of anemia ranged from 16% to 91%, the prevalence of iron deficiency ranged from 22% to 59%, and the prevalence of IDA ranged from 9% to 55%.

In general, trials were considered to have a low risk of bias, with the exception of lack of masking of participants owing to the nature of the intervention (Supplemental Table 7 and Supplemental Figure 1).

Main effects of SQ-LNS on anemia and micronutrient status

Results from the all-trials analyses, inclusive of maternal + child SQ-LNS trials/arms, are presented below, and in Table 2, because the results from the all-trials and child-LNS-only analyses were similar for all outcomes (Supplemental Figures 2A to 2D). Forest plots for all main effects by outcome and individual study are presented below for selected outcomes and as supplemental materials for all other outcomes (Supplemental Figures 3A to 3AA).

SQ-LNS had a significant positive effect on all biomarkers of hematological and iron status (Table 2, Figures 2-3). Compared to control children, hemoglobin concentrations were 2.77 g/L higher among children who received SQ-LNS; additionally, ferritin concentrations were 56% higher, and sTfR and ZPP concentrations were 17% lower among children who received SQ-LNS vs. control. SQ-LNS reduced the prevalence of anemia by 16% (10 percentage points), iron deficiency by 56% (22 percentage points), and IDA by 64% (14 percentage points). Differences in plasma zinc and retinol concentrations between those who received SQ-LNS and those who did not were not significant. RBP concentrations were 7% higher among children who received SQ-LNS compared to the control group. SQ-LNS reduced the prevalences of low and marginal vitamin A status, as measured by RBP, by 56% (3 percentage points) and 22% (8 percentage points), respectively; there was no effect of SQ-LNS on vitamin A status as measured by retinol. We rated the quality of evidence for hemoglobin, ferritin and sTfR concentrations, as well as anemia, moderate-to-severe anemia, iron deficiency, elevated sTfR and IDA as high, based on the GRADE criteria listed above in Methods: at least 6 randomized controlled trials were available for these outcomes and the total sample size was ∼> 2,500, the risk of bias was low, all trials were directly aimed at evaluating SQ-LNS, funnel plots revealed no indication of publication bias, and the direction of the effect was consistent even though the magnitude of the effect across trials differed (i.e., moderate to high heterogeneity). For all other outcomes, we rated the quality of the evidence as low to moderate, primarily because of limited availability of data, i.e. fewer trials and participants.

• Download figure
• Open in new tab

Figure 2:

Forest plot of the effect of SQ-LNS on anemia prevalence

• Download figure
• Open in new tab

Figure 3:

Forest plot of the effect of SQ-LNS on prevalence of iron deficiency (ferritin < 12 µg/L)

Mean differences, ratios of geometric means and prevalence ratios for all outcomes were either identical or greater in random vs. fixed effects models (Supplemental Figures 3A to 3AA). The point estimates of the main effects were similar in the sensitivity analyses in which multi-component arms (e.g. WASH + SQ-LNS) were compared to reference groups that had the same components without SQ-LNS and in which passive control trials were excluded (Supplemental Figures 2A-D). For example, the prevalence ratios for anemia ranged from 0.82-0.84 and those for iron deficiency were 0.36-0.44. There were no differences in statistical significance between models in which outcomes were adjusted vs. not adjusted for inflammation (data not shown).

Effect modification by study-level characteristics

The effects of SQ-LNS on hemoglobin, anemia and biomarkers of iron status, stratified by study-level characteristics, are presented in Figures 4A to 4H, and an overview of these results is presented in Table 3. Forest plots for all outcomes stratified by study-level effect modifiers are presented in Supplemental Figures 4A to 4AA. We were unable to generate pooled estimates for effect modification by any study-level characteristics for ZPP and biomarkers of zinc and vitamin A status (i.e., retinol and RBP) due to the limited number of studies that measured these biomarkers. For iron status biomarkers (ferritin and sTfR), water quality and sanitation sub-groups captured the same trials, so these characteristics are considered as a single effect modifier at the study-level. Effect modification results were generally consistent across all sensitivity analyses (Supplemental Figures 5A to 5AA) and between models in which outcomes were inflammation-adjusted or not (data not shown); the results presented below refer to the all-trials analyses of inflammation-adjusted outcomes.

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 4:

The effect of SQ-LNS provided to children 6-24 months of age compared with a control on (A) hemoglobin concentration, (B) anemia prevalence, (C) moderate-to-severe anemia prevalence, (D) ferritin concentration, (E) iron deficiency, (F) iron deficiency anemia, (G) soluble transferrin receptor concentration, and (H) elevated soluble transferrin receptor, stratified by study-level characteristics. Due to the limited number of studies, we were unable to examine study-level effect modification on all outcomes for all potential modifiers of interest. GMR, ratio of geometric means, MD, mean difference, PR, prevalence ratio, p-diff, p value for the difference in the effect of SQ-LNS between the two levels of the effect modifier.

In all analyses of effect modification by study-level characteristics, the 95% confidence interval of the mean hemoglobin difference, and the ratios of geometric mean ferritin and sTfR concentrations, excluded the null for both strata, indicating that there were significant improvements in hemoglobin, ferritin and sTfR concentrations among children receiving SQ-LNS regardless of study-level characteristics. Similarly, the upper bound of the 95% confidence interval was < 1 for the prevalence ratio and < 0 for the prevalence difference for both categories in all comparisons, indicating that there were significant reductions in the prevalence of anemia, iron deficiency and IDA among children receiving SQ-LNS regardless of study-level characteristics. However, there were some significant interactions, which are described below.

Effect modification by individual-level characteristics

The effects of SQ-LNS on hemoglobin (anemia) and biomarkers of iron status, stratified by individual-level (i.e., child, maternal and household) characteristics, are presented in Figures 5A-5H and an overview of individual-level effect modification is provided in Table 4. Forest plots of all outcomes by potential individual-level effect modifiers are presented in Supplemental Figures 6A to 6AA and 7A to 7AA. For some biomarkers of micronutrient status, we were unable to generate pooled estimates for effect modification by certain potential individual-level effect modifiers because fewer than three trials (comparisons) assessed both the outcome and the effect modifier of interest and/or there were too few individuals with the outcome categorized into each stratum (e.g., ferritin concentration by baseline anemia status or household sanitation). Effect modification results were generally consistent across all sensitivity analyses and between the fixed and random effects models (Supplemental Figures 8A to 8AA). Because all-trials analyses maximized the sample size, some potential effect modifiers were significant in the all-trials, but not in the sensitivity analyses. However, the directionality of effect modification was consistent across all analyses. In addition, results were generally consistent between models in which outcomes were inflammation-adjusted or not (data not shown). Thus, the results presented below refer to the fixed effects models for all-trials analyses of inflammation-adjusted outcomes.

• Download figure
• Open in new tab

• Download figure
• Open in new tab

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 5:

The effect of SQ-LNS provided to children 6-24 months of age compared with a control on (A) hemoglobin concentration, (B) anemia prevalence, (C) moderate-to-severe anemia prevalence, (D) ferritin concentration, (E) iron deficiency, (F) iron deficiency anemia, (G) soluble transferrin receptor concentration, and (H) elevated soluble transferrin receptor, stratified by individual-level maternal, child and household characteristics. For some biomarkers of micronutrient status, we were unable to generate pooled estimates for effect modification by certain potential individual-level effect modifiers due to an insufficient number of comparisons. GMR, ratio of geometric means, MD, mean difference, PR, prevalence ratio, p-for-interaction, p value for the interaction indicating the difference in effects of SQ-LNS between the two levels of the effect modifier.

Main effects of SQ-LNS on anemia and micronutrient status

Children who received SQ-LNS had significantly higher hemoglobin concentrations (2.77 g/L) relative to the control, and SQ-LNS reduced the prevalence of anemia and moderate to severe anemia by 16% (10 percentage points) and 28% (7 percentage points), respectively. Although these effects are smaller than what was reported in the 2019 Cochrane systematic review and meta-analysis of LNS (SQ- or MQ-LNS) for hemoglobin (MD: 5.74 (2.27, 9.30) g/L) and anemia (RR: 0.79 (0.69, 0.90)) (7), our meta-analysis includes a larger number of trials and individual participants (N = 13 trials and 15,562 participants) as compared to the Das et al. meta-analysis (N = 4-5 trials and 2,332-4,518 participants), which increases the precision of the effect estimates. Furthermore, we report estimates for iron deficiency and IDA, which were not included in the previous meta-analysis of SQ- and MQ-LNS. SQ-LNS reduced the prevalence of iron deficiency (plasma ferritin < 12 µg/L) by 56% (22 percentage points) and the prevalence of IDA by 64% (14 percentage points). At endline, the prevalence of IDA across all studies among children in the control groups was 23.5%, compared with 7.9% among children who received SQ-LNS. These large relative and absolute reductions in the prevalence of iron deficiency and IDA due to SQ-LNS are important given that iron deficiency is the most common documented micronutrient deficiency globally (4) and IDA is associated with compromised mental, motor, socio-emotional and neural development (51).

The findings of the present SQ-LNS meta-analysis are similar to those reported in a recent Cochrane systematic review and meta-analysis of the effect of multiple micronutrient powders (MNP) on hemoglobin (MD: 2.74 (1.95, 3.53) g/L) and anemia (RR: 0.82 (0.76, 0.90)) (N = 16-20 trials and 9,927-10,509 participants) (52). Suchdev et al. also reported a 53% reduction in the prevalence of iron deficiency (as defined by trialists) by MNP (N = 7 trials and 1,634 participants); the effect of MNP on the prevalence of IDA was not reported. Another meta-analysis of MNP efficacy trials by Tam et al. reported relative reductions in the prevalence of iron deficiency and IDA of 50% and 55%, respectively (8). Of note, in most of the MNP trials, the dose of elemental iron was 10-12.5 mg/d (primarily as ferrous fumarate), whereas the SQ-LNS trials in our analyses provided only 6-9 mg/d (primarily as ferrous sulfate).

In the present analyses, there was considerable heterogeneity in the effect of SQ-LNS on anemia (reductions ranging from 3 to 29 percentage points), iron deficiency (reductions ranging from 14 to 35 percentage points), and IDA (reductions ranging from 8 to 29 percentage points). This heterogeneity may be due to differences in population characteristics (e.g., baseline prevalence of anemia, iron deficiency and IDA, proportion of anemia attributable to nutritional deficiencies vs. underlying burdens of infection and other causes) and study-design characteristics. The more modest relative reduction in the prevalence of anemia than in IDA may reflect the influence of non-nutritional causes of anemia in these populations (e.g., genetic hemoglobin disorders and infection and inflammation including malaria, intestinal parasites and schistosomiasis). In addition, although SQ-LNS substantially reduced the prevalence of IDA, it did not completely eliminate IDA, possibly reflecting factors such as poor iron absorption (due to anti-nutritional compounds, gastric pH or intestinal or systemic inflammation) (1) or a hemoglobin cutoff for anemia that is set inappropriately high for infants and young children, especially in African populations (53–55). However, it is noteworthy that the endline prevalence of iron deficiency among children who received SQ-LNS was approximately 16% (vs. 40% among children in the control groups), which is comparable to the prevalence of iron deficiency among children 12-36 months of age in the United States of America (13.5%) (56).

We observed significant increases in RBP concentrations among children who received SQ-LNS, although the relative increase was small (7%). The difference in plasma retinol was in the same direction, but not statistically significant. Our ability to draw conclusions was limited due to small sample sizes (n = 663-1236). However, in populations with adequate vitamin A stores, serum retinol may not respond to an intervention due to homeostatic regulation (57). At endline, the prevalence of vitamin A deficiency (retinol or RBP < 0.70 µmol/L) in the control groups was low, ranging from 1.1 to 16.2%. In the majority of studies in this analysis that assessed vitamin A status (7 of 9), more than half of study participants had received high-dose vitamin A supplementation (100,000 – 200,000 IU) within the 6 months prior to outcome assessment. Therefore, in some study contexts, the daily low-dose of vitamin A provided in SQ-LNS may not have provided an additive benefit. However, SQ-LNS did reduce the prevalence of vitamin A deficiency (RBP < 0.70 µmol/L) by 56% (corresponding to a modest 3 percentage point reduction, due to the low overall prevalence of deficiency) indicating the potential of this intervention to improve the status of those at-risk. There was no overall effect of the intervention on plasma zinc concentrations, consistent with results from zinc-fortified food and MNP trials (52, 58), potentially due to the low bioavailability of zinc in SQ-LNS when provided as part of a phytate-rich food matrix (59), or differences in post-absorptive metabolism between zinc supplements and zinc-fortified foods (60).

Effect modification

For both study- and individual-level effect modifiers, it is important to distinguish between the potential to benefit and the potential to respond (18). The potential to benefit is more likely when a population or an individual child is more vulnerable, e.g. due to a high prevalence of anemia or micronutrient deficiencies in the study population at baseline. However, in some cases, children who are more vulnerable may actually be less likely to respond to a nutritional intervention because of other constraints on nutritional status such as infection and inflammation or inadequate care. Thus, we will attempt to frame the following discussion of effect modifiers in this context.

Effect modification by study-level characteristics

Studies included in this analysis were conducted in a variety of geographic and environmental contexts (e.g., different regions, burdens of anemia and infection including malaria, community-level access to improved water, sanitation and hygiene, etc.) and used varying intervention designs (e.g. durations of supplementation, iron dose, frequency of contact between participants and study staff) and this enables us to examine whether these study context and design features modify the effects of SQ-LNS. However, it is difficult to disentangle the impact attributable to one effect modifier from the influence of other characteristics of the study and thus these results should be interpreted with caution. For example, studies that provided a higher iron dose were more likely to provide SQ-LNS supplements for a longer duration, be conducted in South Asia, and have a higher average compliance with supplementation (>80 %), thus making it difficult to disentangle the impact attributable to each specific study-level characteristic. In addition, it is important to note that due to concerns about adverse effects of iron supplementation in malaria endemic areas (61, 62), a number of the SQ-LNS studies in these analyses were purposefully designed to provide a lower iron dose in countries with a high burden of malaria (6).

The effect of SQ-LNS on hemoglobin concentrations was greater in studies with a higher burden of anemia (>60%), suggesting a greater potential to benefit from SQ-LNS in such populations. Similarly, the effect of MNP on hemoglobin concentrations has been shown to be greater in populations that were anemic at baseline vs. populations with mixed/unknown baseline anemia status (MD: 4.53 g/L vs. 3.05 g/L) (52). However, even in populations with a lower burden of anemia, both SQ-LNS and MNP significantly increased hemoglobin concentrations and reduced the prevalence of anemia. In the present analyses, increases in hemoglobin concentrations due to SQ-LNS were not significantly different between populations with and without a high burden of malaria (4.29 g/L vs. 2.59 g/L) or inflammation (3.84 g/L vs. 3.21 g/L). Thus, these results, coupled with the observation that statistically significant effects of SQ-LNS were found in both subgroups, do not support the hypothesis that populations with a high burden of malaria and inflammation have less of a potential to respond to iron interventions due to increased hepcidin concentrations and down-regulation of iron absorption (63, 64).

Effect modification by study-level water quality and sanitation did not reach statistical significance for the majority of hematological and iron status outcomes, with the exception of a greater percentage point reduction in iron deficiency due to SQ-LNS in study sites with a lower proportion of households with access to improved water quality and sanitation. This is likely due to a higher prevalence of iron deficiency among children in the study sites with less access to improved water quality and sanitation; among control group children, prevalence of iron deficiency was 57% in those study sites, compared to 28% in sites with greater access.

Greater reductions in the prevalence of anemia and iron deficiency were observed in trials that provided SQ-LNS for longer than 12 months, compared to a shorter duration (6-12 months). In addition, studies that reported higher average compliance (>80 %) showed greater increases in hemoglobin concentrations and reductions in the prevalence of anemia, but we did not observe significant effect modification by frequency of contact with programmatic or study staff. Finally, we observed greater effects of SQ-LNS on the prevalence of anemia and increase in ferritin concentrations among studies that provided 9 mg/d vs. < 9 mg/d iron. Although it may be difficult to disentangle the impact attributable to each of these aforementioned study-level characteristics, they all suggest a greater effect among studies in which children received a higher total iron dose, either through a longer duration of supplementation, by higher compliance, or a higher daily iron dose. Consistent with this, meta-analyses of the effectiveness of MNP and iron supplements in infants and young children have also shown higher iron doses to have a greater impact on iron and hematological status (8, 52).

Effect modification by individual-level characteristics

The effects of SQ-LNS on hemoglobin concentrations and the prevalence of anemia were greater among children of older mothers compared to those of younger mothers (relative reductions in anemia of 17% vs. 13%, respectively). Similarly, SQ-LNS had a larger effect on both hemoglobin and ferritin concentrations among later-born, as compared with first-born children, and reduced the prevalence of anemia in these sub-groups by 12 vs. 7 percentage points, respectively. SQ-LNS also had a larger effect on stunting, underweight and MUAC among later-born vs. first-born children (19). These results likely indicate a greater potential to benefit among later-born children. For example, hemoglobin concentrations among control group children in this IPD analysis were lower among later-born than first-born children (105.5 g/L vs. 108.4 g/L). Later-born children, who have one or more older siblings, may compete more for caregiving and family resources than first-born children, making them more vulnerable to anemia and iron deficiency and therefore more likely to benefit from nutritional supplementation targeted specifically to young children. In addition, later-born children, who are more likely to be born to older mothers, may be more vulnerable to micronutrient deficiencies due to poor maternal physiological status owing to high fertility rates and short inter-pregnancy intervals (65, 66).

The effects of SQ-LNS on biomarkers of hematological and iron status (i.e., ferritin, sTfR, ZPP) did not differ by child sex, with the exception of greater reductions in ZPP concentrations due to SQ-LNS among males vs. females (24% vs. 18%). The former may have had a greater potential to benefit, given that median ZPP concentrations were higher among control group males than females in this analysis (62.0 µmol/mol heme vs. 53.1 µmol/mol heme), and males tend to be more vulnerable to iron deficiency in infancy (67). However, both sexes responded positively to the intervention, with a 10 percentage point reduction in the prevalence of anemia and a 20-23 percentage point reduction in the prevalence of iron deficiency. Children who were anemic at baseline had greater increases in hemoglobin concentrations due to SQ-LNS than children who were not anemic at baseline, indicating a greater potential to benefit. A recent MNP trial also showed greater increases in hemoglobin concentrations due to MNP among children who were anemic vs. non-anemic at baseline (68). In addition, these results are consistent with our study-level effect modification results, which indicated that increases in hemoglobin due to SQ-LNS were greater in populations with a high vs. moderate burden of anemia. Increases in ferritin concentrations due to SQ-LNS were larger among children who were acutely malnourished at baseline, compared to those who were not. Among children in the control groups, median ferritin concentrations were lower among children with vs. without acute malnutrition (15.5 µg/L vs. 19.5 µg/L), also suggestive of a greater potential to benefit.

Although differences in the ability of populations to benefit or respond to SQ-LNS by the study-level burden of malaria or inflammation appeared to be explained by the cut-off effect, we did observe some differences at the individual level. SQ-LNS reduced the prevalence of anemia by 34% (a 12 percentage point difference) among children without concurrent inflammation vs. 15% (a 5 percentage point difference) among children with elevated CRP and/or AGP concentrations, indicating a greater potential to respond among those without inflammation. As inflammation is itself a cause of anemia (i.e., anemia of chronic disease) and can inhibit absorption of iron (63), it is likely that a higher proportion of anemia in the subgroup of non-inflamed children was amenable to nutritional supplementation. Among children with inflammation, non-nutritional causes of anemia may have been more prevalent (e.g., anemia attributable to acute or chronic infection and inflammation) (29, 69). In the present analyses, the proportion of anemia not due to iron deficiency was greater (54% vs. 35%) among children with inflammation vs. those without. In addition, it is possible that children without inflammation had a greater fractional absorption of iron relative to those with inflammation (70). Hepcidin, an important regulator of systemic iron balance, is elevated by inflammation thereby inhibiting iron absorption (63). While a few trials measured hepcidin, we had insufficient data to examine it in this analysis. However, greater increases in ferritin concentrations due to SQ-LNS were observed among children without inflammation (65% vs. 48%), although there were no differences in the effect of SQ-LNS on iron deficiency by inflammation status.

Greater effects of SQ-LNS on reductions in the prevalence of anemia, and reductions in sTfR concentrations, were seen among children in households with improved (vs. unimproved) water quality. Poor quality water or sanitation may increase the risk of anemia due to infection with soil transmitted helminths or environmental enteric dysfunction, which may increase inflammation or reduce nutrient absorption. Among children in the control group, the prevalence of anemia was higher among children without (vs. with) access to improved water quality (69% vs. 56%). Thus, this effect modification might be seen as consistent with the inflammation effect modification results described above. Children with less exposure to gastrointestinal pathogens through contaminated water supplies may have less inflammation and thus may be more able to respond to the SQ-LNS intervention. However, these findings are in contrast with the observed greater effects of SQ-LNS on anemia and moderate-to-severe anemia among children in households with unimproved (vs. improved) sanitation. This may indicate a greater potential to benefit, given that the prevalences of anemia and moderate-to-severe anemia were higher among control group children in households with unimproved sanitation (by 7 and 10 percentage points, respectively). The contradictory effect modification results for water quality and sanitation are difficult to explain. It is notable, though, that water quality and sanitation did not modify the effect of SQ-LNS on hemoglobin concentrations, and there was evidence of beneficial effects of SQ-LNS in all subgroups of children.

Greater effects of SQ-LNS on ferritin concentrations and the prevalence of iron deficiency were seen among children for whom biomarkers were assessed in the rainy season. Among children in the control groups in this analysis, median ferritin concentrations were lower (13.9 µg/L vs. 16.1 µg/L), and the prevalence of iron deficiency higher (by 6 percentage points) when outcome assessments occurred during the rainy (vs. dry) season. Thus, it is possible that this represents a greater potential to benefit, whereby the supplemental iron provided by SQ-LNS compensates for seasonal differences in dietary intake and/or constraints on iron absorption (e.g., infection and inflammation). However, iron status at a given point in time reflects the cumulative effect of intake, absorption and utilization over many months, so it is unclear whether effect modification by season is due to short-term, acute phenomena or longer-term exposure to adverse conditions that is correlated with season at outcome assessment. Other household-level characteristics, including SES and food security, did not generally modify the effect of SQ-LNS on anemia or iron biomarker outcomes.

With regard to individual-level effect modification of outcomes related to zinc and vitamin A status, observed differences between the stratum-specific point estimates were generally small even when there were statistically significant p-values. In the latter situation, results were generally consistent with effect modification for hematological and iron status biomarkers, whereby children of older mothers, children who were acutely malnourished at baseline, children in households of higher SES and with greater food security, and children assessed during the rainy season had greater increases in biomarker concentrations or reductions in the prevalence of deficiency vs. those in the respective comparison sub-groups.

Strengths and limitations

Strengths of the present analyses include the large sample size, the substantial number of high-quality RCTs available, and the availability of individual participant data for all but one of the eligible trials. In addition, we were able to report the effects of SQ-LNS on multiple indicators of micronutrient status that had not been included in prior meta-analyses. The majority of trials used the same analytical laboratory and platform for several biomarkers (ferritin, sTfR, RBP; Vit-Min Lab) or standardized analytical methods (ZPP), lending strength to the findings. The trial sites were diverse in terms of study context (e.g., burdens of anemia, malaria and inflammation) and design (e.g., iron dose and duration of supplementation), which provided heterogeneity for exploration of study-level effect modifiers. The findings were generally consistent across sensitivity analyses, as well as between fixed- and random-effects models, adding strength to the conclusions.

Several limitations must be considered. Bangladesh was the only country represented in these analyses outside of sub-Saharan Africa. Although hemoglobin data were available for all thirteen trials, fewer studies assessed biomarkers of iron, zinc and vitamin A status (3-7 studies) and sample sizes for each of those biomarkers were smaller (1,133 – 3,078 vs. 15,398 for hemoglobin). In addition, data were not yet available from a sufficient number of studies to be able to investigate the effects of SQ-LNS on additional biomarkers, including plasma hepcidin, folate, and vitamin B12 concentrations. Furthermore, not all trials assessed both CRP and AGP in all children at endline, potentially limiting the accuracy of adjustments for inflammation and/or reducing the available sample size. It should also be noted that a single assessment of inflammation may not adequately characterize the inflammation status of individual children over time, and the effects that average inflammation status over the entire period of supplementation may have on micronutrient status.

Due to limitations in the data (e.g., number of studies that assessed biomarker outcomes or effect modifiers of interest, or a low prevalence of the binary outcome or proportion of children within one of the effect modifier subgroups), we were unable to generate effect estimates of SQ-LNS on all biomarkers by all potential effect modifiers for all trials. Overall, statistical power for study-level effect modification was constrained by the limited number of trials, so there may be meaningful differences in effect estimates between categories of trials even if the p-diff for interaction was not significant. On the other hand, the individual-level effect modification analyses involved multiple effect modifiers and numerous outcomes, so several of the significant p-for-interaction values are likely due to chance. As stated in the Methods section, we did not adjust for multiple hypothesis testing because the effect modification analyses are inherently exploratory. Finally, effect modification results should be interpreted with caution, as potential effect modifiers may be inter-related or confounded by unmeasured variables. This is particularly important for study-level characteristics because, as previously noted, it was not possible to completely disentangle the impact attributable to a specific effect modifier from the impact attributable to other characteristics of the study (e.g., study design, context, implementation, etc.).

Programmatic Implications

The present findings suggest that policy-makers and program planners should consider SQ-LNS in the mix of interventions to prevent anemia and iron and vitamin A deficiencies. The overall effects of SQ-LNS on iron deficiency (56% reduction) and IDA (64% reduction) were substantial and may improve child neurological development and immune function (71). Although the overall effects on anemia and moderate-to-severe anemia were more modest (16% and 28% reductions, respectively), this likely reflects the presence of anemias in these populations that are not nutrition responsive (e.g., genetic hemoglobin disorders and infection and inflammation). Alternative interventions, including micronutrient supplementation, MNP and food fortification are also effective in reducing anemia and the prevalence of iron deficiency (8, 52); however, SQ-LNS provides the added benefits of reducing mortality (72), stunting and wasting (19) and improving developmental outcomes (20).

In terms of program design, the effect modification results herein suggest that a greater impact of SQ-LNS on hematological and iron status outcomes may be obtained by providing formulations with the higher dose of iron (9 mg/d) and/or providing SQ-LNS for the entire window from 6-24 months. The iron dose of fortified products has been of concern because of evidence that iron-containing supplements and MNP may increase susceptibility to malaria in endemic regions, as well as respiratory and gastrointestinal infections (61, 73–75), although two recent systematic reviews and meta-analyses did not indicate any increase in the risk of diarrhea or malaria from these interventions (52, 76). The present analysis did not examine potential adverse impacts (e.g., morbidity or mortality) of SQ-LNS by iron dose, malaria burden or other potential effect modifiers. However, most published trials have not reported differences in diarrheal or malarial morbidity between SQ-LNS and control groups (40, 42–44, 47, 48, 77–79), and some reported beneficial effects of SQ-LNS on diarrheal prevalence (37) and duration of pneumonia, diarrhea and dysentery (35). In addition, a recent meta-analysis reported an overall 27% reduction in the risk of mortality among children who received SQ-LNS vs. control (72). The majority of studies providing the higher iron dose were in lower malaria burden sites (36, 37, 42), and as such, we cannot recommend universal use of higher iron dose SQ-LNS supplements at this time. In areas with a low prevalence of malaria and inflammation, or in malaria endemic areas with a well-integrated control program with appropriate surveillance and the prevention and management of malaria, providing the higher iron dose (9 mg/d) in SQ-LNS may be appropriate and have a greater impact on iron status and hematological parameters. Provision of SQ-LNS containing 9 mg/d iron for 18 months would cumulatively provide approximately 4,925 mg of iron, compared with the 2,200 mg of iron provided by 12 months of SQ-LNS containing 6 mg/d iron, but would increase programmatic costs.

The effect modification results for biochemical outcomes generally did not provide a strong rationale for targeting SQ-LNS only to the most vulnerable children or populations. Even in situations that were indicative of a greater potential to benefit among one sub-group compared to another (e.g., greater increases in hemoglobin concentrations among later-born vs. first-born children and among anemic vs. non-anemic children, greater increases in ferritin concentrations among acutely malnourished vs. non-malnourished children), both sub-groups responded positively and appeared to benefit from the intervention. However, some of the results suggested that a greater impact of SQ-LNS may be obtained by combining supplementation with interventions that address factors related to the potential to respond. Integrating the provision of SQ-LNS with interventions to address the prevention and control of infection and inflammation (e.g., household and/or community level improvements in water, sanitation and hygiene, use of insecticide treated bed nets, and surveillance and treatment of diarrhea and malaria) may increase nutrient (iron) absorption, and thus increase the efficacy of the supplement.

There is now substantial evidence demonstrating the efficacy of SQ-LNS for prevention of anemia and iron deficiency. However, further research is needed to investigate the efficacy of SQ-LNS for prevention of other vitamin and mineral deficiencies. In the present analysis, there was insufficient evidence to assess the effect of SQ-LNS on folate and vitamin B12 status, and no trials assessed status regarding other B-vitamins, vitamin C, vitamin D and vitamin E, or minerals other than iron and zinc. Additional research is also needed on the optimal iron dose in SQ-LNS and the duration of supplementation, with regard to not only iron status and anemia but also morbidity, the costs and benefits of shorter vs. longer supplementation, and the potential to align the intervention with periods of increased vulnerability. Finally, further research would be useful to determine the optimal doses and formulations of micronutrients to include in SQ-LNS, and to investigate the effect of additional compounds, such as phytase or galacto-oligosaccharides, that may improve mineral bioavailability.